We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Genmab AS | NASDAQ:GMAB | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.01 | 7.25% | 29.73 | 28.62 | 29.99 | 29.92 | 29.46 | 29.73 | 721,270 | 00:05:20 |
From May 2023 to May 2024
By Paul Ziobro
AbbVie and Genmab said Tuesday that a clinical trial for a bispecific antibody to treat a form of non-Hodgkin's lymphoma would need further follow up, even after it saw positive topline results.
The Epcore NHL-1 trial is evaluating the safety and preliminary efficacy of epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, in patients with follicular lymphoma.
The companies said topline results showed an overall response rate that exceeded the protocol prespecified threshold for efficacy, while the observed median duration of response wasn't reached, which requires a longer follow up period.
AbbVie and Genmab said they would engage global regulatory authorities to discuss next steps.
"We are encouraged by these topline results, which further support the clinical profile of epcoritamab as a potential therapeutic option for patients with relapsed or refractory follicular lymphoma," said Dr. Mariana Cota Stirner, AbbVie's therapeutic area head for hematology.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
June 27, 2023 19:33 ET (23:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Genmab AS Chart |
1 Month Genmab AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
